Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT402 in Adults With Autism Spectrum Disorder
NCT07303907Phase 2Recruiting
- Sponsor
- Definium Therapeutics
- Start
- Dec 2025
- Primary completion
- Aug 2027
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of R-MDMA in Autism Spectrum Disorder (ASD), sponsored by Definium Therapeutics. Primary endpoint: Numerical Rating Scale at day 15. Started Dec 2025; status: recruiting.
02
Drugs
R-MDMA
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT07303907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07303907.